Cano, AngelaGuzman-Puche, JuliaGarcia-Gutierrez, ManuelCaston, Juan JoseGracia-Ahufinger, IrenePerez-Nadales, ElenaRecio, ManuelNatera, Alejandra MMarfil-Perez, EduardoMartinez-Martinez, LuisTorre-Cisneros, Julian2023-02-082023-02-082019-11-06Cano Á, Guzmán-Puche J, García-Gutiérrez M, Castón JJ, Gracia-Ahufinger I, Pérez-Nadales E, et al. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature. J Glob Antimicrob Resist. 2020 Sep;22:9-12http://hdl.handle.net/10668/14699To describe the case of a patient with infection due to a KPC-producing Klebsiella pneumoniae (K. pneumoniae) isolate developing ceftazidime-avibactam resistance with restored carbapenem susceptibility during ceftazidime-avibactam therapy. To review the clinical/microbiological cure and survival rates using carbapenems in other similar case reports and case series. A patient with an intra-abdominal infection due to K. pneumoniae producing the KPC-48 variant (L169P-A172T) (resistant to ceftazidime/avibactam and susceptible to carbapenems) who was treated with imipenem-cilastatin in combination with tigecycline and gentamicin. The literature was reviewed in order to summarise the in vivo (clinical/microbiological cure and survival rate) use of carbapenems in this emerging scenario. The patient was successfully treated with the indicated regimen. In other reported cases (mostly with pneumonia) all-cause mortality was 50% and clinical cure was 62.5%. Meropenem-vaborbactam has been successful used in an additional case. A carbapenem-based regimen of combination therapy seems to be an option for treating patients infected with K. pneumoniae resistant to ceftazidime/avibactam and susceptible to carbapenems, at least when the risk of mortality is low.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/CarbapenemsCeftazidime/avibactam-resistanceKlebsiella pneumoniaeAnti-bacterial agentsAzabicyclo compoundsCarbapenemsCeftazidimeDrug combinationsHumansKlebsiella pneumoniaeMicrobial sensitivity testsPneumoniaresearch article31733412open accessAntibacterianosCarbapenémicosCeftazidimaCombinación de medicamentosCompuestos de AzabicicloPruebas de sensibilidad microbiana10.1016/j.jgar.2019.11.0072213-7173https://doi.org/10.1016/j.jgar.2019.11.007